Jubilant Pharmova

₹935.30As of Sun 8 Nov 2026, 12:00 UTC

NSE:JUBLPHARMAHealthcare

Country India

PE (Fwd) 35.59

TSR 10Y CAGR 4.05%

Div yield 0.53%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.47

PE TTM 37.29

TSR TTM (13.54%)

Mkt cap ₹146.2B

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹1,031

10.25%

(66.17%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

82.80

Revenue₹B

—

61.30

62.82

67.03

72.34

82.80

88.23

7.80%

14.45

Revenue growth%

—

2.47

6.71

7.93

14.45

6.57

7.32

—

65.16

Gross margin%

—

75.73

66.86

64.92

64.95

65.16

64.89

65.16

9.90

Operating margin%

—

13.70

5.97

7.80

11.15

9.90

9.66

9.90

4.81

Net margin%

—

6.75

(0.97)

1.15

11.60

4.81

4.57

4.81

37.29

P/E ratio (avg)x

—

25.31

—

98.80

17.93

43.30

36.84

34.31

—

18.14

EV/EBITx

—

12.47

15.05

14.56

18.65

21.06

17.44

15.05

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

25.08

EPS₹

—

26.01

(3.83)

4.85

52.84

25.08

25.39

(0.90%)

—

(52.53)

EPS growth%

—

(114.74)

226.62

988.63

(52.53)

1.23

87.05

—

Bookvalue per sh₹

—

FCF per share₹

—

5.00

Dividend per sh₹

—

5.00

5.13

—

0.53

Div yield (avg)%

—

0.76

1.41

1.04

0.53

0.46

0.55

0.76

19.94

Payout ratio%

—

19.23

—

102.88

9.46

19.94

20.22

19.58

—

158.9

Shares (diluted)M

—

159.2

159.1

158.9

◌158.9

(0.04%)

(0.02)

Buyback yield%

—

0.02

0.18

(0.01)

(0.02)

◌—

—

D/E ratiox

—

148.6

Enterprise value₹B

—

104.8

56.40

76.18

150.5

172.6

148.6

13.29%

—

LT debt₹M

—

Peers (US$1.576B)

Cap (US$)

AstraZeneca Pharma…

1.713B

90.31x

NATCO Pharma Limited

1.686B

12.63x

Sudeep Pharma Limited

1.414B

70.86x

Zhuhai Trinomab…

1.581B

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

4.069

3.652

Own earn%

—

Sh yield%

0.52

0.87

Owners

Insiders/Inst%

7.67

23.88

Short interest%

—

SBC / revenue%

0.14

Record

10Y

Profitable years

4/5

Revenue growth years

4/4

EPS growth years

2/4

Dividend streakyrs

Op margin range%

6–14

$1 testx

—

Incr. ROIC%

—

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹82.80B

7.80%

1.00×

Cost of revenue

₹28.84B

17.99%

1.44×

Operating expenses

₹45.76B

4.74%

0.89×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m